DASA Launches Microbial Forensics Competition to Enhance UK Biosecurity
The Defence and Security Accelerator (DASA), in partnership with the Defence Science and Technology Laboratory (Dstl), has launched a new …
News
Tasca Therapeutics Launches with $52 Million to Advance Precision Oncology
Tasca Therapeutics, a biotechnology company focused on small molecule inhibitors for oncology, has raised $52 million in Series A financing. …
Dot Compliance Expands AI Capabilities to Transform Quality and Compliance in Life Sciences
Dot Compliance, a provider of AI-powered compliance and electronic quality management system (eQMS) solutions, has introduced the third generation of …
Cradle Achieves 8x Improved EGFR Binding Over Merck’s Cetuximab in Protein Design Challenge
Cradle’s platform has achieved first place in Adaptyv Bio's protein design competition by producing a novel EGFR-binding protein with a …
AQEMIA Reaches $100 Million in Funding, Plans Expansion and Prepares for Clinical Trials
AQEMIA, a techbio company teaching atomic scale physics to a generative AI, has announced reaching $100 million in cumulative funding. …
Recursion Reports Encouraging Interim Phase 1 Data a Selective CDK7 Inhibitor
Recursion (Nasdaq: RXRX) announced interim findings from the ongoing Phase 1/2 ELUCIDATE trial evaluating REC-617, a precision-designed, oral CDK7 inhibitor …
BioAge Labs Halts STRIDES Phase 2 Trial of Azelaprag-Tirzepatide Combo
BioAge Labs, which recently raised upwards of $198 million through an upsized IPO in September 2024 to fund its clinical …
Vittoria Biotherapeutics Highlights Novel CAR-T Cell Therapy Approach at ASH 2024
Vittoria Biotherapeutics, a Philadelphia-based clinical-stage immunotherapy company, showcased preclinical findings at the 66th Annual American Society of Hematology (ASH) Meeting.
Lantern Pharma Enrolls First Patient in Taiwan for Phase 2 Trial for Never-Smoker Lung Cancer
Following its recent expansion into Japan, Lantern Pharma has now dosed the first patient in Taiwan as part of its …
IDEAYA Demonstrates Preclinical Success with PRMT5 Inhibitor IDE892
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a clinical-stage precision medicine oncology company, announced the nomination of IDE892, a potent and selective …
Cherry Biotech Publishes Research on Advanced Skin-on-Chip Model in Microfluidics
Cherry Biotech has announced the publication of research on its CubiX platform in Advanced Healthcare Materials. The study explores a …
Antag Therapeutics Secures €80 Million to Advance GIPR-Based Obesity Therapies
Following the FDA’s October 2024 clearance of Antag Therapeutics’ Investigational New Drug (IND) application for its lead molecule, AT-7687, the …